RxDoctor Payments DataLook up a doctor →

Adrienne Pan, DO

Neurology · Las Vegas, NVNPI 1790123925

Payments from drug & device makers

$5,733in general payments, 2019–2025

Across 293 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$714
  • AbbVie$536
  • UCB, Inc.$517
  • Biogen$372
  • Amgen$251
  • SK Life Science, Inc.$250
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$5,709100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,733 in reported general payments places this provider in the 60th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$69,621
Medicare patients
214
Services billed
534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab16$152,838
Gamunex-CImmune Globul G/Gly/Iga Avg 4616$137,474
MayzentSiponimod11$104,937
BriviactBrivaracetam20$28,806
QuliptaAtogepant22$23,510
XcopriCenobamate13$15,560
UbrelvyUbrogepant15$14,598
Dalfampridine ErDalfampridine26$11,705
Aimovig AutoinjectorErenumab-Aooe15$11,237
Ajovy SyringeFremanezumab-Vfrm13$8,788
Lacosamide62$7,522
Levetiracetam156$3,796
Oxcarbazepine60$3,483
Gabapentin168$3,397
Lamotrigine134$3,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$71$137,47416 claims
NovartisMayzent$714$104,93711 claims
AbbVieQulipta, Ubrelvy$536$38,10837 claims
UCB, Inc.Briviact$517$28,80620 claims
SK Life Science, Inc.Xcopri$250$15,56013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 145 neurology providers in Nevada.

Other neurology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →